All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD79B chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD79B. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD79B antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Mature B cell neoplasms.
CAR Construction : SN8-CD28-41BB-CD3ζ Fig.1 Analysis of exhaustion markers and immune checkpoint molecules. The expression of multiple exhaustion markers of untransfected, CAR19-transfected, CAR79b(CB3-1)-transfected, and CAR79b(SN8)-transfected T cells, was assessed, and the proportions of T cells expressing diferent immune checkpoint molecules were not signifcantly diferent. Ding, S., Mao, X., Cao, Y., Wang, N., Xu, H., & Zhou, J. (2020). Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Targeted oncology, 15(3), 365-375. |
CAR Construction : SN8-CD28-41BB-CD3ζ Fig.2 In vitro cytotoxicity of CAR cells. B-cell lymphoma cell lines (SU-DHL-10, CA46, Ramos, HMy2.CIR, and Jeko-1) and molm13 in cytotoxicity assays at various efector: target cell ratios. Ding, S., Mao, X., Cao, Y., Wang, N., Xu, H., & Zhou, J. (2020). Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Targeted oncology, 15(3), 365-375. |
CAR Construction : SN8-CD28-41BB-CD3ζ Fig.3 Determination of cytokines release. After T cells were co-cultured with diferent B-cell lymphoma cell lines or molm13, the intracellular interferon (IFN) expression of untransfected, CAR-T cells were fow cytometrically measured. Ding, S., Mao, X., Cao, Y., Wang, N., Xu, H., & Zhou, J. (2020). Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Targeted oncology, 15(3), 365-375. |
CAR Construction : SN8-CD28-41BB-CD3ζ Fig.4 Antitumor response of CAR-T cells in vivo. In vivo antitumor efects of untransfected, CAR19-transfected, CAR79b(CB3-1)-transfected, and CAR79b(SN8) T cells were assessed in NCG mice bearing Ramos-fLUC cells Ding, S., Mao, X., Cao, Y., Wang, N., Xu, H., & Zhou, J. (2020). Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Targeted oncology, 15(3), 365-375. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD79B (SN8) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP2778). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION